In view of the fact that the OFA includes some relevant genes in melanoma pathways apart from BRAF, such as NRAS, KIT, or MAP2K1, we embraced this panel to prospectively study a series of advanced melanoma patients. The gene discussed is MAP2K1; the disease is melanoma.